A Study of Ibandronate [Bonviva/Boniva] and Alendronate in Female Patients With Post-Menopausal Osteoporosis

Roche

Status: Completed

Conditions: Postmenopausal Osteoporosis

Treatments: Drug: ibandronate [Bonviva/Boniva]; Drug: alendronate

Study type: Observational

Funder types: Industry

Identifiers

NCT01128257

ML22927

Details and patient eligibility

About

This observational study will assess the compliance and persistence of patients, real life efficacy and safety of intravenously quarterly administered 3 mg ibandronate [Bonviva/Boniva] in comparison to oral alendronate generics in female patients with post-menopausal osteoporosis. The anticipated time of assessment is 12 months. The target sample size is 5000-7000 patients.

Enrollment: 6,054 patients

Sex: Female

Ages: 55+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients, >/= 55 years of age
• Postmenopausal osteoporosis
• Patients who are in the opinion of the physician eligible to participate in this study

Exclusion criteria

• N/A

Trial design

6,054 participants in 2 patient groups

1

Treatment:

Drug: ibandronate [Bonviva/Boniva]

2

Treatment:

Drug: alendronate